Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | CASP6 | P55212 | 1/20 | 0.69 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.64 |
| ▸ | RB1 | P06400 | 3/20 | 0.59 |
| ▸ | CDC42 | P60953 | 1/20 | 0.57 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | CDKN1A | P38936 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | BRD3 | Q15059 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16433492 | 0.93 | GAA (0.71) | GAACASP6PRMT5RB1CDC42 | |
| SCHEMBL4187019 | 0.89 | GAA (0.72) | GAACASP6PRMT5RB1CDC42 | |
| SCHEMBL5461934 | 0.89 | PRMT5 (0.69) | GAACASP6PRMT5RB1CDC42 | |
| SCHEMBL4165396 | 0.89 | GAA (0.66) | GAACASP6PRMT5RB1CDC42 | |
| Hydrochloric Acid SCHEMBL4158259 | 0.88 | GAA (0.74) | GAACASP6PRMT5RB1CDC42 | |
| SCHEMBL22135890 | 0.88 | CDC42 (0.56) | GAACASP6PRMT5RB1CDC42 | |
| SCHEMBL22135891 | 0.88 | CDC42 (0.56) | GAACASP6PRMT5RB1CDC42 | |
| SCHEMBL5428515 | 0.87 | GAA (0.64) | GAACASP6PRMT5RB1CDC42 | |
| SCHEMBL5468186 | 0.87 | PRMT5 (0.66) | GAACASP6PRMT5RB1SIRT1 | |
| SCHEMBL22135733 | 0.86 | CYP2D6 (0.70) | GAACASP6PRMT5RB1CDC42 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11529354-B2 | Methods and compositions for the treatment of tuberculosis | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-12-20 | — | — | US | disclosed |
| US-11529354-B2 | Methods and compositions for the treatment of tuberculosis | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-12-20 | — | — | US | disclosed |
| US-20220062233-A1 | Compounds for the Reduction of the Deleterious Activity of Extended Nucleotide Repeat Containing Genes | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2022-03-03 | — | — | US | disclosed |
| EP-3612534-B1 | PROCESS FOR THE PREPARATION OF PIPERAZINE RING FOR THE SYNTHESIS OF PYRAZINOCARBAZOLE DERIVATIVES | TECNIMEDE SOCIEDADE TECNICO MEDICINAL SA (PT) | 2021-12-22 | — | — | EP | disclosed |
| US-20210137932-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF TUBERCULOSIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-05-13 | — | — | US | disclosed |
| WO-2020131573-A1 | COMPOUNDS FOR THE REDUCTION OF THE DELETERIOUS ACTIVITY OF EXTENDED NUCLEOTIDE REPEAT CONTAINING GENES | NUREDIS, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| US-20200147069-A1 | Compounds for The Reduction of The Deleterious Activity of Extended Nucleotide Repeat Containing Genes | THE BOARD OF TRUSTEES OF LELAND STANFORD JUNIOR UNIVERSITY | 2020-05-14 | — | — | US | disclosed |
| WO-2019050890-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF TUBERCULOSIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2019-03-14 | — | — | WO | disclosed |
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | CHIRON CORPORATION | 2007-11-29 | — | — | US | disclosed |
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | CHIRON CORPORATION | 2007-11-29 | — | — | US | disclosed |
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | CHIRON CORPORATION | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | MAVS, SARS1, ZC3HAV1 | GAA 1417/4885CASP6 3264/4885PRMT5 1060/4885 |
| US-20220062233-A1 | Compounds for the Reduction of the Deleterious Activity of Extended Nucleotide Repeat Containing Genes | NSUN2, RTCB, RRM2B | GAA 1448/4885CASP6 1719/4885PRMT5 1001/4885 |
| US-11529354-B2 | Methods and compositions for the treatment of tuberculosis | IFNG, FNTB, TYMS | GAA 492/4885CASP6 857/4885PRMT5 2931/4885 |
| US-20200147069-A1 | Compounds for The Reduction of The Deleterious Activity of Extended Nucleotide Repeat Containing Genes | NSUN2, RNMT, RRM2B | GAA 1007/4885CASP6 2464/4885PRMT5 691/4885 |
| US-20210137932-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF TUBERCULOSIS | IFNG, FNTB, TYMS | GAA 492/4885CASP6 857/4885PRMT5 2931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.